MedAdNews
August, 2005
Most Recognized Gastrointestinal Brands
The most-recognized gastrointestinal brand in North America is Prevacid. The brand was most recognized by 10% of physicians in a survey conducted by Brand Institute Inc. in the first quarter of 2005. Marketed by Tap Pharmaceutical Products Inc. (tap.com), Prevacid is composed of lansoprazole and was approved by FDA in May 1995. The product is approved for indications in symptomatic gastroesophageal reflux disease, nonsteroidal anti-inflammatory drug-associated gastric ulcer, duodenal ulcers, Helicobacter pylori infection, pathological hypersecretory conditions, heartburn, active benign gastric ulcer, all grades of erosive esophagitis, active duodenal ulcers, and nonsteroidal anti-inflammatory drug-associated gastric ulcers.
Prilosec was the second most-recognized gastrointestinal brand in North America. About 9.9% of physicians recognized this brand the most. Composed of omeprazole, Prilosec is marketed by AstraZeneca
(astrazeneca.com) and was approved by FDA in September 1989. Prilosec is approved for indications in Helicobacter pylori infection, duodenal ulcers, heartburn, erosive esophagitis, pahtological hypersecretory conditions, and acute benign gastric ulcer.
AstraZeneca also markets the third most-recognized gastrointestinal brand in North America, which is Nexium. The brand was most recognized by 9.3% of physicians. Nexium contains esomeprazole and was approved by FDA in February 2001. The product is approved for indications in H.pylori infection and duodenal ulcer disease, erosive esophagitis, heartburn, gastroesophageal reflux disease, and gastric ulcers.
Brand Name Development
The most-recognized gastrointestinal brand in Europe was Losec. Omeprazole, the active chemical in Losec, is Known as Prilosec in the United States. About 7.2% of physicians recognized this brand as the most-recognized brand. In the European Union, Losec is approved for indications in duodenal ulcers, duodenal peptic ulceration, pathological hypersecretory conditions, severe reflux esophogitis, and recurrent reflux esophagitis. Losec is marketed by AstraZeneca.
Zantac was the second most-recognized gastrointestinal brand in Europe. About 6.8% of physicians recognized this brand the most. In the UK, Zantac is approved for indications in duodenal and benign gastric ulcers, postoperative ulcers, esophageal reflux disease. Zollinger-Elison syndrome, chronic episodic dysepsia, gastroesophageal reflux disease, nosteroidal anti-inflammatory drug-asscoiated gastric ulcers, stress ulceration, recurrent hemorrhage from peptic ulcer, and Mendelson syndrome. Zantac is marketed by GlaxoSmithKline (gsk.com).
The third most-recognized brand in Europe was Nexium. About 5% of physicians recognized this brand the most. Nexium was approved in the European Union in July 2000. The product is approved for indications in erosive reflux esophagitis, long-term treatment of patients with healed esophagitis to prevent relapse. H. pylori, nonsteroidal anti-inflammatory drug-associated gastric ulcers and dudenal ulcers, and gastroesophageal reflux disease.
Brand Institute Inc. (BrandInstitute.com) surveyed more than 2,000 physicians and hospital and retail pharmacists in North America and Europe to determine the most-recognizable brands in the category of gasterointestinal drugs. Brandpoll is a marketing tool designed to help clients monitor the competitive marketplace and identify the potential strengths and weakness of their brands.
Brand Name Development
